<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="144492">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01743885</url>
  </required_header>
  <id_info>
    <org_study_id>8638</org_study_id>
    <nct_id>NCT01743885</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Propranolol Versus Acebutolol on the Proliferative Phase of Infantile Hemangioma</brief_title>
  <official_title>Efficacy and Safety of Propranolol Versus Acebutolol on the Proliferative Phase of Infantile Hemangioma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Montpellier</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Montpellier</source>
  <oversight_info>
    <authority>France: The Commission nationale de l’informatique et des libertés</authority>
    <authority>France: Agence Nationale de Sécurité du Médicament et des produits de santé</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      There is no effective treatment for hemangioma regardless of immediate severity. That is in
      this respect a orphan disease. These hemangiomas, sometimes large, will have a phase of
      proliferation of several months (very scary for parents) and regression over several years.
      The natural history is peppered with local complications (ulcers) and aesthetic and
      psychological sequelae (sometimes major for the child and the family). The effects of
      acebutolol and propranolol on the proliferative hemangiomas were discovered accidentally by
      two French teams (Montpellier for acebutolol and Bordeaux for propranolol). Acebutolol and
      propranolol have been used for many years for the treatment of hypertension and congenital
      heart disease, including infants, with few side effects. The effects of acebutolol and
      propranolol were immediately visible with reduced volume and skin whitening of the
      hemangioma. In a preliminary study, acebutolol was administered to 20 patients in
      Montpellier with big regression of hemangiomas. The aim of the study was to compare the
      clinical efficacy of acebutolol (10mg/Kg/jour) and propranolol (3mg/Kg/j) on the
      proliferative phase of infantile hemangioma in infants.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2012</start_date>
  <completion_date type="Anticipated">February 2016</completion_date>
  <primary_completion_date type="Anticipated">November 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Hemangioma size</measure>
    <time_frame>3 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>It will be evaluated using a VAS (visual analogue scale) on a series of photos at Day 0, Day 30 and Day 90</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tolerance of treatment</measure>
    <time_frame>3 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>All adverse events are collected at each visited</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients requiring treatment with corticosteroids because of the evolution of a 'serious' hemangioma</measure>
    <time_frame>3 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Hemangioma</condition>
  <arm_group>
    <arm_group_label>propanolol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Propanolol (Syprol:oral solution)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Acebutolol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Acebutolol (Sectral:oral solution)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Acebutolol</intervention_name>
    <description>10 mg/kg/jour in 2 doses during 90 days after gradual increase of doses in the first week</description>
    <arm_group_label>Acebutolol</arm_group_label>
    <other_name>Sectral</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Propanolol</intervention_name>
    <description>3 mg/kg/jour in 3 doses during 90 days after gradual increase of doses in the first week</description>
    <arm_group_label>propanolol</arm_group_label>
    <other_name>Syprol</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Infants under 6 months

          -  Presenting a hemangioma with the following characteristics:

               -  subcutaneous and / or cutaneous

               -  minimum diameter of 1.5cm on face, 5cm outside face and 3cm if it is ulcerated.

               -  without functional impairment requiring treatment or vital corticosteroid

          -  Consent of both parents (or the person having parental authority in families)

          -  Which at least one parent is a beneficiary of a social security system.

        Exclusion Criteria:

          -  Indication of treatment with corticosteroids for an indication other than hemangioma

          -  Indication of treatment with beta-blocker for another indication that the hemangioma

          -  Infant presenting cons-indications for the administration of acebutolol or
             propranolol:

               -  Asthma and chronic obstructive pulmonary disease in their severe forms.

               -  Heart failure controlled by treatment.

               -  Cardiogenic shock

               -  Prinzmetal Angina

               -  Bradycardia (&lt;80 beats / min at rest the first month &lt;70/minute from 1 to 6
                  month).

               -  Raynaud's phenomenon and peripheral arterial disorders in their severe forms.

               -  Pheochromocytoma untreated.

               -  Low blood pressure (blood pressure &lt;60/30 mmHg before 6 months)

               -  Hypersensitivity to acebutolol or propranolol

               -  History of anaphylactic reaction.

               -  Treatment with amiodarone and / or calcium channel blockers.

               -  Congenital heart disease outside inter auricular communication (CIA) or inter
                  ventricular communication (CIV) insignificant
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>6 Months</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michèle Bigorre, PH</last_name>
    <role>Principal Investigator</role>
    <affiliation>UH Montpellier</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Michèle Bigorre, PH</last_name>
    <email>m-bigorre@chu-montpellier.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>UH Lyon</name>
      <address>
        <city>Lyon</city>
        <zip>69130</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Isabelle JAMES, MD</last_name>
      <email>i.james@valdouest.fr</email>
    </contact>
    <investigator>
      <last_name>Isabelle JAMES, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UH Marseill</name>
      <address>
        <city>Marseille</city>
        <zip>13385</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Alain FRAISSE, MD</last_name>
      <email>alain.fraisse@ap-hm.fr</email>
    </contact>
    <investigator>
      <last_name>Alain FRAISSE, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chirurgy Plastic Department</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michele Bigorre, MD</last_name>
      <email>m-bigorre@chu-montpellier.fr</email>
    </contact>
    <investigator>
      <last_name>Michele BIGORRE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UH NCaremeau</name>
      <address>
        <city>Nîmes</city>
        <zip>30000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Myriam MARQUE, MD</last_name>
      <email>myriam.marque@chu-nimes.fr</email>
    </contact>
    <investigator>
      <last_name>Myriam MARQUE, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 10, 2014</lastchanged_date>
  <firstreceived_date>November 28, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hemangioma</keyword>
  <keyword>Beta-blocker</keyword>
  <keyword>Acebutolol</keyword>
  <keyword>Propranolol</keyword>
  <keyword>Randomized controlled trial</keyword>
  <keyword>Infants</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hemangioma</mesh_term>
    <mesh_term>Hemangioma, Capillary</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Acebutolol</mesh_term>
    <mesh_term>Propranolol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
